In particular, three positron emission tomography (PET) studies using [18F]ASEM, an α7 nAChR antagonist, showed reduced binding in cingulate, frontal, parietal, temporal, occipital cortices as well as in subcortical regions including thalamus, striatum, and hippocampus [76,77,78] of schizophrenia patients compared to healthy individuals. The gene discussed is CHRNA7; the disease is schizophrenia.